Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Medarex up on Pfizer antibody deal

On Monday, MEDX was up $1.01 (15%) to $7.84 on 10.5 million shares after it signed a 10-year deal with

Read the full 200 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE